12:00 AM
 | 
Feb 02, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Arhalofenate: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 32 patients with gout showed that 7%, 43% (p<0.05) and 79% of patients receiving once-daily 600 mg oral arhalofenate plus 40 mg febuxostat and 20%, 93% (p<0.001) and 100% (p<0.01) of patients receiving once-daily 800 mg oral arhalofenate plus 40 mg febuxostat achieved sUA levels of <4, <5 and <6 mg/dL at day 29, respectively, vs. 0%, 7%...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >